Acrivon Therapeutics Inc
ACRVLatest QuantConomy context for ACRV: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
Acrivon Therapeutics Inc
QuantConomy has a structured record for ACRV. More descriptive asset metadata will appear here when the platform record includes it.
- Symbol
- ACRV
- Name
- Acrivon Therapeutics Inc
- Coverage
- 3 market/data records
- Sources
- alpaca fmp alphavantage sec nasdaq
Recent signals for ACRV
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| fundamental eps change | very bullish | 76 | May 13, 12:00 AM | ACRV (Q1 2026, diluted eps): EPS grew 75.7% ($-2.02 → $-0.49). [sequential period basis, very bullish signal] |
| fundamental net income change | very bullish | 76 | May 13, 12:00 AM | ACRV (Q1 2026, net income): grew 75.6% (-$77.91M → -$19.04M). [sequential period basis, very bullish signal] |
| fundamental operating income change | very bullish | 76 | May 13, 12:00 AM | ACRV (Q1 2026, operating income): grew 76.3% (-$84.11M → -$19.90M). [sequential period basis, very bullish signal] |
FUNDAMENTAL signals are experimental: the generator was recently enabled and coverage is still being validated.
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| ACRV | NASDAQ | alpaca | Acrivon Therapeutics, Inc. Common Stock |
| ACRV | NASDAQ | fmp | Acrivon Therapeutics, Inc. Common Stock |
| ACRV | NASDAQ | alphavantage | Acrivon Therapeutics Inc |
Recent insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | BAUM CHARLES M | Director | grant | 20,275 | — | — | 4 on EDGAR |
| Jun 17, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | grant | 20,275 | — | — | 4 on EDGAR |
| Jun 17, 2026 | TOMSICEK MICHAEL JOHN | Director | grant | 20,275 | — | — | 4 on EDGAR |
| Jun 17, 2026 | Palani Santhosh | Director | grant | 20,275 | — | — | 4 on EDGAR |
| Jun 17, 2026 | Shacham Sharon | Director | grant | 20,275 | — | — | 4 on EDGAR |
| Jun 17, 2026 | Magovcevic-Liebisch Ivana | Director | grant | 20,275 | — | — | 4 on EDGAR |
| Jun 17, 2026 | DiRocco Derek | Director | grant | 20,275 | — | — | 4 on EDGAR |
| May 21, 2026 | Blume-Jensen Peter | President and CEO | other | 13,729 | $1.79 | $24,575 | 4 on EDGAR |
| May 18, 2026 | DiRocco Derek | Director | grant | 9,366 | $0.00 | $0 | 4 on EDGAR |
| May 18, 2026 | TOMSICEK MICHAEL JOHN | Director | grant | 9,366 | $0.00 | $0 | 4 on EDGAR |
| May 18, 2026 | Palani Santhosh | Director | grant | 9,366 | $0.00 | $0 | 4 on EDGAR |
| May 18, 2026 | Devroe Eric | Chief Operating Officer | grant | 72,981 | $0.00 | $0 | 4 on EDGAR |
| May 18, 2026 | Blume-Jensen Peter | President and CEO | grant | 180,095 | $0.00 | $0 | 4 on EDGAR |
| May 18, 2026 | Peterson Katharine | Chief Accounting Officer | grant | 14,227 | $0.00 | $0 | 4 on EDGAR |
| May 18, 2026 | Levy Adam D. | Chief Financial Officer | grant | 46,167 | $0.00 | $0 | 4 on EDGAR |
| May 18, 2026 | Miller Mary | Chief Legal Officer | grant | 49,830 | $0.00 | $0 | 4 on EDGAR |
| May 18, 2026 | BAUM CHARLES M | Director | grant | 9,366 | $0.00 | $0 | 4 on EDGAR |
| May 18, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | grant | 9,366 | $0.00 | $0 | 4 on EDGAR |
| May 18, 2026 | Mirza Mansoor Raza | Chief Medical Officer | grant | 38,817 | $0.00 | $0 | 4 on EDGAR |
| May 18, 2026 | Gamelin Erick | Chief Development Officer | grant | 38,584 | $0.00 | $0 | 4 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Query ACRV context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access